The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...
It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...
Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...
While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results